Cellectis presents preclinical evidence that MUC1 CAR T cells reduce triple-negative breast cancer while maintaining safety Page 1

NEW YORK, Sept. 3, 2024 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its breakthrough gene editing platform to develop life-saving cell and gene therapies, today published a scientific paper in Science Advances suggesting that TALEN-edited MUC1 CAR T-cells could be a potential treatment option for patients with advanced triple-negative breast cancer (TNBC) with limited therapeutic options.

Worldwide, breast cancer is still the most common malignancy in women. Of all subtypes, triple-negative breast cancer (TNBC) stands out as the most aggressive form with a high metastatic potential and poor survival rates.